Spanish drugmaker Grifols says Brookfield’s potential €6.45-billion offer undervalues the company

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 10 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 92%

Streetwise News

Business Business Latest News,Business Business Headlines

Earlier on Tuesday, Brookfield said it was considering a public offer for Grifols at €10.50 per A share and €7.62 per B share, implying a company valuation of €6.45-billion

potential €6.45-billion offer significantly undervalued the Spanish drugmaker’s prospects and long-term potential.

Grifols said its board would meet later on Tuesday to consider the potential offer, but that, given the valuation, it would not be in a position to recommend that shareholders accept it.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 5. in BUSİNESS

Business Business Latest News, Business Business Headlines